



![]() |
Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients |
|
Authors | ![]() | |
Published in | Neuro-Oncology. 2019 | |
Abstract | Peptide vaccines offer the opportunity to elicit glioma-specific T cells with tumor killing ability. Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted with poly-ICLC in HLA-A2 + glioma patients. | |
Identifiers | PMID: 30753611 | |
Full text | ||
Structures | ||
Research groups | Immunobiologie des tumeurs du cerveau (669) Immunothérapie des cancers (42) La Sclérose en plaques (908) Optimisations des techniques avancés en neuroimagerie (985) | |
Citation (ISO format) | MIGLIORINI, Denis et al. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. In: Neuro-Oncology, 2019. doi: 10.1093/neuonc/noz040 https://archive-ouverte.unige.ch/unige:120077 |